ASAM 47th Annual Conference - Innovations in Addiction Medicine and Science - 2016 (69 CME)

Product not yet rated

The ASAM Annual Conference is the nation's premiere event providing the latest innovations and scientific developments in addiction medicine. The program includes exciting changes in format and structure to provide learning in a more interactive, casual and fun environment.

Meeting highlights include; symposia, workshops, poster presentations, special focus sessions and fun events designed to allow more effective learning and networking. Participate in the front-running conference that specializes in addiction medicine:

  • Learn about new tools for diagnosis, treatment, patient care and public policy
  • Explore the newest research and developments shaping the future of addiction medicine
  • Network with medical professionals, researchers, leading scientists and policy advocates
  • Find out about the latest science from leaders of federal agencies and institutions
  • Discover evidence-based techniques, tools, technologies and practices
  • Engage in discussions about strategies of integration of addiction medicine and primary care
  • Participate in special on and off-site sessions that dive into substance use in Baltimore and the programs that seek to address it.

 

  • Evaluation and Certificate - 47th Annual Conference

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    CME Evaluation for the ASAM Annual Conference.

    Download the CME Tracking Sheet to assist with recording sessions attended at the conference. Complete the course evaluation first and then claim credits. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

  • Population Health: The Promise, Perils, and Pitfalls of the Electronic Health Record (1 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    The mandate to adopt electronic health records (EHR) has created great promise and opportunity throughout medicine. The promise has been in efforts to meaningfully use the information contained in the EHR to improve patient safety and outcome. With this opportunity comes challenge. In this focus session, three principal investigators from the NIDA Clinical Trials Network will share their work covering the promise, perils, and pitfalls of the electronic health record as related to the identification, treatment, and privacy of patients who use alcohol, tobacco, and other drugs. Dr. Li-Tzy Wu will show a population health initiative that identifies comorbid mental health and substance use diagnoses in Type 2 diabetics. Dr. Katharine Bradley will address systems quality improvement through EHR initiatives on marijuana and alcohol screening in primary care settings. Dr. Gavin Bart will address the complexities of privacy protections in the era of the EHR and solicit audience feedback on how privacy protections are implemented within their EHR.

    The mandate to adopt electronic health records (EHR) has created great promise and challenge throughout medicine. The promise has been in efforts to meaningfully use the information contained in the EHR to improve patient safety and outcome. With this opportunity comes challenge. In this focus session, three principal investigators from the NIDA Clinical Trials Network will share their work covering the promise, perils, and pitfalls of the EHR as related to the identification, treatment, and privacy of patients who use alcohol, tobacco, and other drugs. Dr. Li-Tzy Wu will share her experience in utilizing a large EHR data warehouse with data from more than 170,000 adults to identify comorbid substance use and mental health diagnoses in patients with type 2 diabetes mellitus (T2DM). Prevalent diagnoses among adults with T2DM were mood (21.22%), SUD (17.02%: tobacco 13.25%, alcohol 4.00%, drugs 4.22%), and anxiety diagnoses (13.98%). The data sets allow for identification of risk groups in general medical settings that can be used to inform the need and structure of collaborative care models and to identify utilization patterns. Dr. Katharine Bradley will describe collaboration with health system clinical and IT leaders to integrate marijuana and drug screening into the EHR. Working in a learning healthcare environment, these partnerships have allowed over 12,000 patients to be screened in the first 6-months. She will present rates of drug and marijuana screening, rates of standardized substance use disorders assessment for high risk patients, and rates of marijuana- and drug- related discussions documented in primary care progress notes. How this process allows for greater monitoring of practice performance and impact on HEDIS measures for initiation and engagement of patients with drug use disorders in care at the level of health system, practice, and practitioner will be discussed. Dr. Bradley will also discuss the challenges of obtaining meaningful data from the EHR progress note through automated natural language processing. Given the high prevalence of marijuana use and the focus of health plans nationwide on HEDIS measures, she will facilitate an audience discussion of perceptions of primary care “best practices" for addressing marijuana use and for improving HEDIS measures. Dr. Gavin Bart will address the complexities of patient privacy protections as specified in 42 CFR Part 2 in the age of the EHR. These protections enacted more than 40 years ago could not have predicted the adoption of the EHR and the integration of addiction and general medical care. Whether 42 CFR Part 2 hampers patient safety through the segregation of medical information in EHRs or threatens the ability to improve population health through the analysis of data in EHR and claims/utilization databases will be discussed. Because there is little understanding of the variability in how the rule is interpreted by health systems, the audience will be encouraged to share their experiences in how the rule has influenced their EHR roll out and ability to track patience centered outcomes and utilization.

    Gavin Bart

    MD, PhD, FACP, DFASAM

    Dr. Gavin Bart is Director of the Division of Addiction Medicine at Hennepin County Medical Center and Associate Professor of Medicine at the University of Minnesota. He received his MD from the University of Minnesota and trained in internal medicine at the Hennepin County Medical Center. His PhD is in experimental and clinical pharmacology, also from the University of Minnesota. He trained in addiction medicine at The Rockefeller University where he continued as Director of Clinical Research until moving to Minnesota where is is co-PI of the NorthStar Node of the NIDA Clinical Trials Network. His areas of expertise include clinical pharmacology and the pharmacological management of opioid dependence. 

    His current research areas include the population pharmacokinetics of methadone, genetic influences of methadone pharmacology and treatment outcome, electronic health record privacy provisions of 42 CFR Part 2, and clinical decision support tool development for SUD. 

    He is Chair of the Life-Long Learning and Self-Assessment committee for the American Board of Addiction Medicine and is ASAM Region VI (IA, IL, IN, MI, MN, WI) director. Internationally, he is co-director of the SAMHSA-funded Vietnam HIV and Addiction Technology Transfer Center and provides ongoing technical assistance for the Substance Abuse and Mental Health Administration in South East and Central Asia.

    Ryan Caldeiro

    MD

    Ryan Caldeiro obtained his medical degree from Case Western Reserve University School of Medicine in Cleveland, OH. He then completed residency training in Psychiatry and Addiction Psychiatry from the University of Washington in Seattle. During his education and training, he participated in research studies exploring pharmacotherapies for addictive disorders and treatment outcomes for patients with co-occurring chronic pain. Upon completing training, he joined Group Health Cooperative of Washington, where he serves as the Chief of Chemical Dependency Services and Consultative Psychiatry. Group Health is both the largest medical group in Washington State, providing integrated multispecialty care, as well as the largest HMO in Washington State. In his position, he oversees clinical delivery of services for substance use disorder care within the physical healthcare delivery system and provides medical leadership in directing health plan operations as it administers chemical dependency benefits for its members within a contracted network of providers. He also oversees consultative psychiatry services. Within the medical group, he works closely with Primary Care leadership and primary care providers in evaluating and managing patients with substance use disorders and developing capacity and support for delivery of office based buprenorphine in primary care settings developing integrated behavioral health services which includes screening, assessment and population management for patients with depression and substance use disorders. He continues with research activities through the Group Health Research Institute with investigations in collaborative care models for patients with substance use disorders.

    Li-Tzy Wu

    ScD, RN, MA

    Dr. Wu is a Professor in the Department of Psychiatry and Behavioral Sciences at Duke University Medical Center, Durham, North Carolina, USA. She received pre-doctoral and post-doctoral training in psychiatric and drug addiction epidemiology from the School of Public Health at the Johns Hopkins University, Baltimore, Maryland. She is one of the node Principal Investigators of the National Drug Abuse Treatment Clinical Trials Network.

    Katharine A.Bradley

    MD, MPH

    Katharine Bradley, MD, MPH is a general internist and health services researcher who, for the past 25 years, has conducted research on how alcohol-related care can be practically integrated into medical settings. She is Senior Investigator at Group Health Research Institute, Affiliate Professor of Medicine and Health Services at University of Washington, and Associate Investigator at Veterans Affairs (VA) Puget Sound Health Care System in the U.S. Her research has included validation of the 3-item AUDIT-C and collaboration with VA clinical and quality leaders to implement alcohol screening and brief alcohol interventions in over 900 VA sites nationwide. Ongoing research includes the NIAAA-funded CHOICE trial of nurse-delivered collaborative care for alcohol use disorders (AUDs); an NIAAA-funded study developing a patient decision aid for AUDs; and a pragmatic trial of implementation of alcohol screening, brief alcohol interventions, and shared decision making for AUDs across 25 primary care clinics in a regional integrated health delivery system in the U.S. Dr. Bradley is currently supported by an NIAAA Mid-career Mentoring Award and is a multiple PI, along with Drs. Weisner and Campbell, on the new Health Systems Node of the NIDA Clinical Trials Network. Finally, NIDA CTN has funded pilot research on marijuana and drug screening in 3 primary care clinics which Dr. Bradley will be presenting at ASAM.

  • CNS Pharmacogenetics Determine Pain Perception, Opioid Risk, Addiction Treatment and Non-Opioid Alternatives (1 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 credits while learning about CNS Pharmacogenetics (PGx) studies of pain, addiction risk and treatment. Our goal is determining which variants (single nucleotide polymorphisms: SNPs) affect patient's pain perception, require higher analgesic doses, increase opioid risk, and affect treatment outcome. While various SNPs predict pain sensitivity and opioid risk; their value is during the acute injury before chronic pain and opioid use. The discovery of COMT SNPs grouped into low, average and high pain sensitivity haplotypes has been reproduced in clinical studies showing prolonged morbidity in high pain sensitive patients with TMJ disorders, motor vehicle accidents and postherniotomy pain. Additional SNPs include voltage-gated sodium and calcium channel variants with new non-opioid treatment. Melanocortin-1, associated with red hair, and new research correlates eye color with pain tolerance. SNPs associated with addiction include Dopamine: DRD2, ANKK1, DRD4, DBH and DAT1. GABA α 2 correlates with adult addiction, yet in adolescents, rule-breaking behaviors. Additional SNPs with opioid risk include serotonin transporter 5HTTLPR and STin2, COMT and BDNF vs. the protective effects of Vasopressin/Oxytocin system. Finally the δ and κ opioid receptors are reviewed.

    Pharmacogenetics (PGx) studies the treatment of pain management [1] addiction risk [2] and medication-assisted treatment [3]. Precision medicine focuses on single nucleotide polymorphisms (SNPs) in the DNA that encode for receptors, transporters and other CNS enzyme variants. Our goal is determining which SNPs affect patient's exaggerated pain perception [4] require higher doses of analgesics [1] and be at increased risk of opioid or other addiction [2] along with response/treatment outcome[3]. Despite isolating various SNPs, the end result depends upon multiple feedback pathways to up- or down-regulate the mRNA and production of proteins (GABA, glutamate, serotonin & dopamine receptors, transporters, etc.) within the mesocorticolimbic pathway stimulating the Ventral Tegmental Region [VTA] to Nucleus Accumbens [NAc] dopamine release, among other pathways [5]. Similarly, the feedback loop of the Raphe Nucleus on afferent nociceptive pain fibers and the Locus Coeruleus on afferent neuropathic pain fibers are integral to new discoveries of non-opioid pain treatments [6]. While various SNPs help predict pain sensitivity and risk of substance abuse; these analyses need to be done early during the acute phase of injury, or pain process. The longer a patient is on opioids stimulating NAc dopamine release, regulation feedback on RNA affects protein/receptor density. An early pain study found Catechol-o-methyltransferase (COMT) Val158Met variant having reduced activity and subsequent increased OPRM1 receptor density due to continuous dopamine bombardment down-regulating natural endorphin production [7]. The original discovery of 4 COMT SNPs grouped into three haplotypes, low, average and high pain sensitivity [4] has continued to be reproduced from the bench to the bedside in clinical studies showing exaggerated and prolonged pain in high pain sensitive patients in TMJ disorders, minor motor vehicle accidents [8] and postherniotomy pain [9] adding GTP cyclohydrolase (GCH1) to the COMT. Additional SNPs include the calcium channel complex subunit CACNA2D2, which increased sensitivity to opioid treatment [10], and the importance of voltage-gated sodium channel variants in new non-opioid pain treatments [11]. Several of these SNPs also have significant affects based upon gender [12]. Melanocortin-1, closely associated with red hair color has some equivocal findings with pain sensitivity, and new research correlates eye color with pain tolerance. Several key SNPs associated with opioid abuse and addiction includes Dopamine: DRD2, ANKK1, DRD4, DBH and DAT1 [13] but varies by the allele in regards to addiction risk vs. another allele in poor responders to buprenorphine [14] Other SNPs correlating with addiction include GABA α 2 (GABRA2) in adults, but race specific as some variants were addiction protective in African Americans [15]. In adolescents it was associated with rule-breaking behaviors that may lead to addiction vulnerability [16]. Additional SNPs with opioid risk include serotonin transporter, SLC6A4, specifically 5HTTLPR and STin2, COMT, BDNF [17] including stress-related reward affects on DA release in the NAc and protective effects of Vasopressin/Oxytocin system in reducing addiction and relapse [18]. Finally the importance of the δ and κ opioid receptors will be reviewed.

    Daniel A. Schwarz

    MD, CMRO, FASAM

    Dr. Schwarz obtained his M.D. from the University of Illinois at Chicago, and then completed his Surgery Residency at the University of Toledo, becoming Board Certified in 1994. He combined productive surgical research at the University of Michigan, while an active Level-1 Trauma Surgeon/Clinical Instructor of Surgery at the University of Toledo. After a business sabbatical, he returned to the University of Michigan where he expanded the Craniofacial Research Lab, was awarded several grants, research awards and co-authored an NIH RO1 funded grant, with Steven Buchman, MD. He mentored a dozen students, fellows and some residents.

    Recognizing increased opioid abuse in surgical and pain management patients, he pursued a formal Addiction Medicine fellowship at St. John's Brighton Hospital under John Hopper, MD, becoming Board Certified in 2010. He initiated the first prospective study correlating addiction after gastric bypass, published 2010. He became MRO certified, is CLIA high-complexity certified in toxicology, and laboratory director for office EIA and reference LC-MS/MS laboratories. He practices pain management and addiction medicine, specializing in co-occurring disorders, primarily ADHD. He was Medical Director for Summit Diagnostics, LLC, overseeing both toxicology and Pharmacogenetics (PGx), and then became Chief Medical Advisor for Iverson Genetics, educating physicians before joining Proove Biosciences as Executive Director R&D;Medical Director Pain and Addiction. He authored and was P.I. for two large IRB approved, multi-center longitudinal studies on pain and PGx, and commercialized a reproducible pain perception PGx test, originally published in 2004. He went on to develop his own PGx algorithms in pain and addiction, as Principal of JAS Consulting, LLC, and interprets genetic tests for physicians, while speaking, educating, and consulting. He is currently authoring three manuscripts: Pain Management, Addiction Medicine and PGx in Toxicology for Elsevier's Clinics in Laboratory Medicine series.

    Mark K. Greenwald

    PhD

    Mark Greenwald, Ph.D. (tenured Professor) is the Associate Chair for Research, and directs the Substance Abuse Research Division, its Human Pharmacology Laboratory and outpatient opioid treatment clinic in the Dept. of Psychiatry and Behavioral Neurosciences at Wayne State University (WSU) School of Medicine in Detroit, Michigan. He is jointly appointed in the WSU Dept. of Pharmacy Practice. Dr. Greenwald has published about 90 research papers and book chapters, and over 165 research abstracts. His research program focuses on (1) pharmacological, environmental and individual difference – including genetic – determinants of drug seeking/use as they relate to progression, persistence and relapse problems; (2) using brain-imaging techniques (e.g. PET to measure mu-opioid receptors, MRS to measure glutamate), pharmacokinetics, and behavioral phenotyping (laboratory models of drug motivation) to advance the clinical neurobiology of substance use disorders; and (3) developing novel medication and behavioral treatments for substance use disorders (e.g. opioid, cocaine and cannabis). The National Institutes on Health (NIH) has continuously funded his research since 1996. He has been principal investigator and co-investigator on many federally funded grants (especially related to opioids and buprenorphine treatment), has consulted for pharmaceutical companies related to emerging addiction medicine products, regularly reviews grant applications and has peer-reviewed manuscripts for more than 30 substance abuse and psychiatric journals. He is a past President of Division 28 (Psychopharmacology and Substance Abuse) of the American Psychological Association. Dr. Greenwald proudly mentors tenure-track junior faculty members, medical residents, postdoctoral fellows, graduate students, postbaccaulaureate, and undergraduate honors students.

    Inna Belfer

    MD, PhD

    Inna Belfer, MD PhD is a human geneticist with a primary interest in the relationship between genes and complex traits such as human pain, psychiatric diseases, and addictions. Her research focuses on identifying genetic and pharmacogenomic signatures predicting acute and chronic pain and analgesic response. Dr. Belfer is a nationally and internationally recognized expert in human pain phenotyping and genotyping as well as in modifiers of genetic effects on pain, analgesia and opioid addiction. Currently Dr. Belfer is a Clinical Analyst at the Division of Analgesic, Anesthetic and Addiction Products at the Food and Drug Administration. In addition she is an Adjunct Professor of Medicine and Human Genetics at the University of Pittsburgh, Pittsburgh, Pennsylvania and an Adjunct Professor of Neuroscience at McGill University, Montreal, Canada.

  • The Role of Screening, Brief Intervention and Referral to Treatment Everyone’s Business (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Screening, Brief Intervention and Referral to Treatment (SBIRT) is a public health approach to identifying and addressing substance use in our patients. The SBIRT model will be examined via a panel presentation. Each presenter will provide examples of SBIRT implementation in a variety of settings (health and community health) and the utilization of technology-based SBIRT delivery systems. The panel will examine what role SBIRT can play with patient’s health and wellness.

    Screening, Brief Intervention and Referral to Treatment (SBIRT) is a public health approach to identifying and addressing substance use in our patients. The SBIRT model will be examined via a panel presentation. Each presenter will provide examples of SBIRT implementation in a variety of settings (health and community health) and the utilization of technology-based SBIRT delivery systems. The panel will examine what role SBIRT can play with patient's health and wellness. At the end of the session participants will be able to: understand the Screening, Brief Intervention and Referral to Treatment (SBIRT) model and the role it can play with patient's health and wellness, describe technology-based interventions that deliver SBIRT in a variety of health care settings and apply SBIRT to their current work environment. The goal of this presentation is to create a community of providers who share a passion for reducing and/or eliminating substance use problems in society.

    Peter Luongo

    PhD

    Before joining IRETA in 2011, Dr. Peter Luongo worked in the behavioral health field for over thirty years as a social worker and administrator. In Maryland, Dr. Luongo was the Single State Authority under three governors as the director of the Department of Health and Mental Hygiene Alcohol and Drug Abuse Administration. He also served within the Montgomery County, MD Department of Health and Human Services for over two decades in a variety of clinical and administrative leadership roles. He received his B.A. and M.A. in Psychology from The Catholic University of America and his Ph.D. in Social Work from the University of Maryland. Dr. Luongo has served as a faculty associate at Johns Hopkins University where he received the Johns Hopkins University Excellence in Teaching Award in 1996. In 2008, he received the Maryland Social Worker of the Year award from the National Association of Social Workers and in 2012, he was selected as one of “50 Heroes for Justice” by The University of Maryland School of Social Work. In 2015 Dr. Luongo was nominated and elected a Class A Trustee of the General Services Board of Alcoholics Anonymous.

    Richard L. Brown

    MD, MPH

    Dr. Brown is a family physician and a tenured full professor in the Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin. His academic focus has been the primary care management of alcohol and drug disorders and other behavioral risk factors and conditions. He has conducted NIH-funded research, published dozens of peer reviewed articles, made numerous presentations, and conducted workshops in these realms on four continents. He served as president of the Association for Medical Education and Research in Substance Abuse (AMERSA) from 1997 to 1999 and received AMERSA's McGovern award for excellence in medical education in 2002. From 1999 to 2004, he served as the founding director of Project MAINSTREAM (www.projectmainstream.net), a federally funded program that enhanced substance abuse education for twelve health professions and improved education for over 10,000 trainees. Since 2006, he has served as Director for the Wisconsin Initiative to Promote Healthy Lifestyles (www.wiphl.com). WIPHL has helped 40 general healthcare settings provide over 110,000 screens and 25,000 interventions, garner excellent patient satisfaction, and elicit substantial declines in risky and problem drinking. Dr. Brown is owner and CEO of Wellsys, LLC (www.wellsys.co), which provides software, consulting, training and clinical support to enable healthcare settings to provide systematic, evidence-based, cost-saving screening and intervention services for the behavioral risks and disorders responsible for over 40% of deaths, most chronic disease and disability and nearly $1 trillion in costs per year.

    Thomas Freese, PhD

    Principal Investigator and Co-Director, Pacific Southwest Addiction Technology Transfer Center (Pacific Southwest ATTC, HHS Region 9)

    Thomas E. Freese, Ph.D., received his doctorate degree in clinical psychology from the California School of Professional Psychology in 1995. Dr. Freese is currently the Director of Training for UCLA ISAP, Principal Investigator and Director of the SAMHSA-funded Pacific Southwest Addiction Technology Transfer Center (PSATTC, HHS Region 9), and Principal Investigator and Co-Director of the SAMHSA-funded Center of Excellence on Racial and Ethnic Young Men Who Have Sex with Men and Other Lesbian, Gay, Bisexual, and Transgender Individuals (YMSM+LGBT CoE). Dr. Freese has served as Principal Investigator on projects funded by the California Department of Alcohol and Drug Programs and Department of Health Care Services to train providers to implement Screening, Brief Intervention, and Referral to Treatment (SBIRT). Dr. Freese has also led several large projects that assist providers in implementing integrated treatment for co-occurring mental health and substance use disorders. He has been a featured presenter at conferences and meetings nationally and internationally on the impact and treatment of methamphetamine and opioid dependence. In addition, Dr. Freese has served as the Project Director on a number of studies including research on methamphetamine use. He has worked in the addiction field since 1983, and has developed and conducted trainings in 45 states and internationally, providing training and workshops for clinicians-in-training at the all levels.

    Brian Suffoletto

    MD, MS

    Brian Suffoletto, MD MS, is an Assistant Professor in the Dept. of Emergency Medicine at the University of Pittsburgh. As a clinical investigator, he has developed a specific focus on designing and evaluating mHealth interventions that use time-varying EMA data to understand contextual and time-varying contributors to substance use. He is currently a recipient of a K23 award from the NIAAA with a focus on advancing the science of adaptive mHealth alcohol interventions and a co-Investigator on an R34 from the NIAAA focused on testing a telemedicine and text message platforms aimed at reducing alcohol misuse among community college students. He is also a co-Investigator on a NIDA-Emergency Medicine Foundation grant to study the potential effectiveness of a text messaging program on substance use relapse rates and is conducting pilot studies that use mobile phone sensor data to predict alcohol use occasions. Based on these experiences, he has found that mobile communication devices can be powerful tools to understand substance use, but balancing design between data collection and usability is critical for success.

  • Overview of Addiction Medicine (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Using The ASAM Principles of Addiction Medicine, fifth edition as a guide, presenters will review articles spanning neurobiology, pharmacology, intoxication and withdrawal, screening and diagnosis, treatment, mutual help, and special topics and populations.

    This symposium will provide a rapid review of recent updates from the scientific literature from 2015 to 2016 in addiction medicine. We will begin with articles related to the neurobiology of addiction and progress to epidemiology, pharmacology, intoxication and withdrawal syndromes, screening and diagnosis, mutual help, special topics including harm reduction, special populations including the criminal justice population, and end with an overview of addiction treatments including pharmacologic and behavioral interventions. We will review key articles from the past twelve months, with a focus on those published in high impact factor journals and studies with particularly noteworthy findings. We will structure this as a "rapid-fire journal club" and will encourage audience participation. We will also discuss implications of research findings and possible relevance to clinical practice. The goal of this symposium is to provide the learner with a concise, structured, and evidence-based summary of the most recent scientific evidence in the field using The ASAM Principles of Addiction Medicine, fifth edition as a guide.

    Sarah Wakeman

    MD, FASAM

    Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

    Joshua D. Lee

    MD, MSc, FASAM

    Joshua D. Lee MD, MSc is an Associate Professor in the Departments of Population Health and Medicine at the NYU School of Medicine. He is board-certified in Internal Medicine and Addiction Medicine and is a physician at Bellevue Hospital Center, NYU Langone Medical Center, and in the NYC jails. He directs the NYU ABAM Fellowship in Addiction Medicine. His research focuses on novel and medication treatments for addiction among criminal justice and primary care populations.

  • Reduction in Drug Use and Improved Health (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    For the first time a seminal finding shows that reduction in drug use is associated with improved health in general. Specifically we will show that reduction in cocaine use by chronic cocaine users improves their cardiac health and this can be diagnosed by measuring plasma levels of Endothelin-1, a biomarker of coronary endothelial function.

    Reduction in Drug Use and Improved Health Jag H. Khalsa, MS, PhD, National Institute on Drug Abuse, NIH, USA Ivan Montoya, MD, National Institute on Drug Abuse, NIH, USA In 2014, an estimated 27 million people aged 12 or older were current users of an illicit drug in the United States. Although only an estimated 1.5 million were the cocaine users in the US, worldwide, an estimated 13-19 million people used cocaine in the past year. Drug use is associated with serious morbidity and mortality. Besides affecting the CNS, cocaine abuse is also associated with cardiovascular disease (CVD). It is projected that in 2030, an estimated 24 million people will die from CVD. In addition, not only HIV infection is associated with cardiovascular complications, but the highly active antiretroviral therapy (HAART) that has substantially reduced AIDS-related mortality and thus non-HIV-related mortality, is also increasingly associated with CVD. In this symposium, the clinician/researchers, Drs. Shenghan Lai (Johns Hopkins) and Alex Manini (Mount Sinai, NY) will present their latest research on cocaine and HIV-associated CV effects, and also show that reduction in cocaine use is associated with improved cardiac health. Further, they will also discuss the role of various biomarkers in diagnosing cardiovascular effects of stimulants including cocaine and amphetamines in HIV infected substance abusing populations. Dr. David Fiellin (Yale), By using the Veterans Aging Cohort Index (VACS), Dr. David Fiellin (Yale) will present his research on reduced drug use and improved health in a Veterans cohort of HIV-infected individuals on opioid agonist therapy. We will also discuss the latest funding opportunities available at NIDA/NIH.

    Jag Khalsa

    PhD, MS

    Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology/medicine, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: jk98p@nih.gov

    Shenghan Lai

    MD, MPH

    Professor of Pathology, Radiology, Psychiatry, Medicine & Epidemiology

    John Hopkins University School of Medicine

    Alex Manini

    MD, MS

    Dr. Manini is Associate Professor of Emergency Medicine at the Icahn School of Medicine at Mount Sinai in New York City, where he is the Co-Director of the Medical Toxicology Division, and Associate Director of the Clinician Scientist Training Program (T32) in Emergency Care Research. He is an established, independent investigator with a track record in clinical investigation related to drug overdose, substance use, and emergency medicine, with over 60 peer-reviewed publications. He is currently PI on a NIDA R01 entitled "Predicting adverse cardiovascular events due to drug overdose emergencies". His completed funding includes a career development award from the National Institute on Drug Abuse, as well as grants from the City of New York, the New York State Department of Health, the Emergency Medicine Foundation, and the Medical Toxicology Foundation.

    David A. Fiellin

    MD, FASAM

    Professor of Medicine, Investigative Medicine and Public Health

    Yale University School of Medicine

    Ivan Montoya

    MD, MPH

    Dr. Montoya is the Deputy Director of the Division of Therapeutics and Medical Consequences (DTMC) and Senior Medical Officer at the National Institute on Drug Abuse (NIDA). He received an M.D. from the University of Antioquia (Colombia), a Masters in Public Health from The Johns Hopkins School of Public Health, and completed residency training in Psychiatry at the University of Antioquia and the University of Maryland Hospital (Baltimore). He was a Fulbright-Hubert H. Humphrey Fellow at The Johns Hopkins School of Public Health, Visiting Foreign Fellow at the Intramural Research Program of NIDA, Director of the Practice Research Network of the American Psychiatric Association, and consultant for the World Health Organization's Pan American Health Organization. He has published extensively in the areas of etiology, prevention, treatment (pharmacological and non-pharmacological), and medical consequences of drug abuse.

  • Medication Assisted Treatment for Tobacco Addiction: Putting Evidence into Practice (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    Tobacco is the most common addiction for which medications are approved by the FDA to treat this deadly addiction. However, due to a variety of system, patient and practitioner level barriers, medication assisted treatment is rarely offered. Moreover, the presence of comorbidities such as other addictions or mental illnesses inhibit practitioners from assisting tobacco addicted individuals. This workshop will review the evidence base on the use of FDA approved smoking cessation medication in these populations. Learners will understand how to prescribe combination therapy safely. The session will be case based and interactive with a focus on safety while using medications to assist tobacco addicted individuals achieve and maintain a permanent remission.

    Tobacco addiction is the leading cause of preventable death in North America, killing nearly half a million North Americans every year. Current smokers are more likely to be less educated, live in poverty and suffer from other addictions and or mental health disorders. The USPTF in September 2015 provided Grade A evidence to intervene with every smoker. Addiction treatment and primary care settings are optimal to provide combined evidence based behavioural and medication assisted treatment. , However, a lack of specialized knowledge in medication assisted treatment for tobacco addiction pose a challenge to adapting and tailoring treatment for patients with other mental illnesses and or addictions. Additionally, the challenge of variable motivation and firmly held beliefs regarding tobacco use pose a challenge for practitioners and patients.

    This workshop will assist practitioners adapt the latest evidence to their patients with comorbid addictions and or mental illnesses.  This dynamic and interactive session will give attendees practical, relevant knowledge and skills to incorporate evidence-based approaches to tobacco dependence treatment in their practice, with particular emphasis on adapting and tailoring pharmacotherapy for patients with co-morbid conditions. Attendees will leave the session with a better understanding of how to recommend and prescribe pharmacotherapy for tobacco addicted individuals and explore evidence-based approaches for patients with mental health problems as well. This session emphasizes learner engagement, interaction and practice though large and small group discussions, case-based learning and reflective exercises. Workshop participants will receive links to clinical tools and resources to facilitate sharing with colleagues and community stakeholders.

    Peter Selby

    MBBS, CCFP, FCFP, DFASAM

    Peter Selby MD is the Director of Medical Education and a Clinician Scientist at the Centre for Addiction and Mental Health. He is a Professor in the Departments of Family and Community Medicine, Psychiatry, and the Dalla Lana School of Public Health at the University of Toronto. He is also a Clinician Scientist in the Department of Family and Community Medicine. Dr. Selby is the Executive Director and creator of the TEACH project; a continuing education certificate program in Applied Counselling for Health with a focus on smoking cessation, through the University of Toronto. Dr. Selby’s research, as a Principal Investigator at the Ontario Tobacco Research Unit, includes smoking cessation especially in smokers with co-morbid conditions. As the Principal Investigator of the STOP Study, he investigates the effectiveness of NRT and counselling in different types of intervention settings. He is also the PI of CANADAPTT- a unique Canadian Smoking Cessation Guideline development and dissemination project. Dr. Selby also continues his clinical research with pregnant women who use substances and is the PI of a knowledge translation program (PREGNETS) to increase the adoption of evidence-based interventions with pregnant smokers. 

    He has received grant funding totaling over 80 million dollars from CIHR, NIH, and Ministry of Health and has published 130 peer reviewed publications. He has published 5 books (including 4 edited), is the author of 30 book chapters, and 32 research reports prepared for the government. He is the Co-Chair for the Ministry of Health Cessation Task force and the Chair of the Canadian Centre on Substance Abuse National Task Force on Treatment for Prescription Drug Misuse. Dr. Selby mentors Fellows in Addiction Medicine and Addiction Psychiatry, junior investigators and medical students. Dr. Selby a sought after speaker for various topics including addictive disorders, motivational interviewing, and health behavior change.

  • President’s Symposium - Advances in Pain Management: Collaborative Solutions to a Complex Problem (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    ASAM’s President will lead an in-depth exploration into new developments in the field of pain management. This high-level symposium will not only explore the difficult overlap between chronic pain and addiction but also the complexities of inter-professional collaboration.

    ASAM's President will lead an in-depth exploration into new developments in the field of pain management. This high-level symposium will not only explore the difficult overlap between chronic pain and addiction but also the complexities of inter-professional collaboration. Collaboration is ubiquitous and necessary for many of the healthcare innovations of the past few years. Presenters will discuss new changes in pain management that are being promoted by the AMA and how these changes will affect the medical culture surrounding pain treatment. Experts will also discuss inter-professional management issues and the patients who have chronic pain and a high risk of addiction. Doctors have found that some patients will feel abandoned if their pain medicine is stopped suddenly. Physicians and other members of the care team need to help their patients understand the risk of brain changes and how to use alternatives to addictive pain medicines to develop a new lifestyle. This session will provide a new viewpoint on the present and future of pain management

    R. Jeffrey Goldsmith

    MD, DLFAPA, DFASAM

    Dr. Goldsmith began his addiction medicine career in 1974 as a medical student, learning about the disease of alcoholism as a counselor for one of the Department of Transportation's Alcohol Safety Action Projects. He received his medical training at the University of Cincinnati College of Medicine from 1973-1977 and finished his residency in Psychiatry at UC in 1981.

    Recent Employment history

    In 1994 Dr. Goldsmith joined the VA fulltime. From 1994-2009, he split his time between Dual Diagnosis Services and other duties including all of the psychiatric consultations for the hospital (1994-1997) and research with the Clinical Trials Network (1995-2009). He was an active member of Cincinnati's NIDA research group, and Cincinnati's principal investigator for its pivotal study of buprenorphine/naloxone for opiate addiction. Dr Goldsmith also created an integrated Primary Care Mental Health program with the director of Primary Care, initiated in 2007 and still active.

    Currently Dr. Goldsmith works in the VA Buprenorphine Treatment Clinic.

    Teaching

    In 1994, Dr. Goldsmith developed an ACGME accredited Addiction Psychiatry Fellowship and the following year was funded by the Dept. of Veterans Affairs for a two year Addiction Medicine Fellowship. He holds the title of Professor of Clinical Psychiatry in the Department of Psychiatry and Behavioral Neuroscience at the University of Cincinnati. He was addiction fellowship director from 1989 to 2007 and continues to teach in addiction fellowships: Psychiatry and ABAM.

    ASAM involvement

    Dr. Goldsmith joined ASAM in 1984, became ASAM certified in 1986 and got his CAQ in Addiction Psychiatry in 1994. He has been on the CME committee since then, and was its chair for nine years from 2000-2009. Dr Goldsmith is President of ASAM 2015-2017.

    Mark A. Weiner

    MD, DFASAM

    Dr. Weiner received his undergraduate degree (B.S. Psychology) at the University of Michigan, Ann Arbor. He earned his medical degree at Cornell University Medical College in New York City. He completed his internship and residency in Internal Medicine at Northwestern University McGaw Medical Campus in Chicago, Illinois. He is Board Certified in Internal Medicine and Addiction Medicine. Since 2008, Dr. Weiner has worked at Pain Recovery Solutions in Ann Arbor, Michigan practicing full time Addiction Medicine and Pain Medicine. He is the Section Head of Addiction Medicine at Saint Joseph Mercy Hospital - Ann Arbor. He has participated in planning the ASAM preconfernece, Common Threads: Pain and Addiction, since 2011 and is the current vice chair. He also is a member of the ASAM Annual Meeting planning committee since 2014 and is an editor on the up-and-coming ASAM Pain and Addiction Handbook.

    Herbert L. Malinoff

    MD, FACP, DFASAM

    I am the president and founder of Pain Recovery Solutions and began this private practice in 1999. I am certified in Internal Medicine, Pain Management, Addiction Medicine, and Medical Oncology. I specializes in treating patients with chronic pain syndromes, addiction, and in detoxification as well as internal medicine needs. I have the understanding of the relationship between medical problems, pain, and addiction led to the establishment of a practice that provide services to patients that address multiple related problems using an integrated, comprehensive approach. I received my Medical Degree from the University of Michigan in 1978. I trained in Internal Medicine at Michael Reese Hospital in Chicago, and completed fellowships in Hematology/Oncology and Nuclear Medicine at the University of Michigan. I have an associate degree in Healthcare Risk Management and Quality Review. I present lectures internationally on Chronic Pain and Addiction and am an active member of the American Society of Addiction Medicine where I am co-chairman of the Pain and Addiction-Common Threads Course. I am a Fellow of both the American College of Physicians and the American Society of Addiction Medicine. I am the immediate past president of the Michigan Society of Addiction Medicine and on the faculty of the Department of Anesthesia at the University of Michigan Medical Center. No Disclosures

  • The ASAM Policy Plenary—Parity and the ACA: Implementation Update and Issues on the Horizon for Addiction Medicine (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    The 2016 Policy Plenary will address ongoing opportunities and challenges inherent in implementing health reform and the specific patient protections of the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008. Participants will hear a general update on the status of the law’s implementation, specifically as it relates to commercial insurance plans and Medicaid managed care plans. Speakers representing the health plans, physicians, and law enforcement will also discuss how physicians can better work with payers to ensure patients can access evidence-based addiction care, the practical application of MHPAEA to health plans, how physicians and patients can use the law to file coverage determination appeals, and the unique challenges of enforcing the law.

    The 2016 Policy Plenary will address ongoing opportunities and challenges inherent in implementing health reform and the specific patient protections of the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008. Participants will hear a general update on the status of the law's implementation, specifically as it relates to commercial insurance plans and Medicaid managed care plans. Speakers representing the health plans, physicians, and law enforcement will also discuss how physicians can better work with payers to ensure patients can access evidence-based addiction care, the practical application of MHPAEA to health plans, how physicians and patients can use the law to file coverage determination appeals, and the unique challenges of enforcing the law.

    Kelly Clark

    MD, MBA, DFASAM, DFAPA

    Dr. Kelly J. Clark is the President Elect of ASAM. She currently chairs the Public Policy Council, consisting of the Legislative Advocacy, Payer Relations, and Public Policy Committees.

    Board certified in addiction medicine and psychiatry, she has focused her career on issues of prescription drug abuse, evidence informed behavioral health care, and payment reform. Dr. Clark is Chief Medical Officer of CleanSlate Centers, a multi-state medical group currently treating over 5,000 opioid addicted patients with medication management, and which has received a SAMHSA Science to Service Award for Office Based Opioid Treatment. She is active on the Association of Managed Care Pharmacy's Addiction Treatment Advisory Group; served on the writing committee of the Johns Hopkins Bloomberg School of Public Health's recent policy document, “The Prescription Drug Epidemic: An Evidence Based Approach”; and led the workgroup on Health Systems and Reimbursement at SAMHSA's Buprenorphine Summit.

    As the Behavioral Health Medical Director of CDPHP, a non-profit health plan in New York, she provided the clinical leadership for in-sourcing the management of behavioral health benefits. As Chief Medical Officer for Behavioral Health Group, she again focused on opioid addiction. Her expertise in payment models, quality metrics, medical-behavioral health integration, and clinical care delivery systems, as well as her clinical work treating people with addictive disease, all allow her to offer insights and recommendations to address the current epidemic.

    As faculty of the University of Massachusetts Medical School for eight years, Dr. Clark trained students and resident physicians on addiction. She is currently a member of the American Psychiatric Association's Integrated Care Work Group; the National Rx Drug Abuse Summit Advisory Board; and the faculty of the Virginia Tech Carilion School of Medicine.

    Sam Muszynski

    JD

    senior policy advisor and director parity implementation and enforcement

    American psychiatric association

    Doug Nemecek

    MD, MBA

    Dr. Doug Nemecek helps set the groundwork for clinical coordination, quality and integration for Cigna's behavioral health and health and wellness operations. As co-chair of the National Quality Improvement Committee overseeing the company's quality program, he helps ensure network access and availability, patient safety, compliance for treatment with clinical guidelines, participant and provider satisfaction and utilization management. Dr. Nemecek oversees 15 Medical Directors in clinical operations, and is the chief medical liaison for integration, quality and operations. Additionally, he works directly with customers to mold operations and provides clinical expertise in new and existing program development.

    Since joining Cigna in 2002, Dr. Nemecek has helped establish workflows, protocols, and collaborative procedures to create a unified medical management team across the company. Additionally, he continues to develop unique relationships with our network providers to ensure members and providers achieve the best possible outcomes.

    Prior to joining Cigna, Dr. Nemecek served as Executive Medical Director for Allina Behavioral Health Services in Minneapolis, overseeing five outpatient clinics and four inpatient mental health units with over 80 mental health providers. He also has 10 years of clinical experience with an inpatient and outpatient psychiatric practice in Minneapolis.

    Dr. Nemecek received his M.D. and completed his psychiatric residency at Washington University in St. Louis in 1993. He is recognized as a Distinguished Fellow with the American Psychiatric Association, is board certified by the America Board of Quality Assurance and Utilization Review Physicians and holds an M.B.A. from the University of St. Thomas in Minneapolis.

    Michael D. Reisman

    JD

    Michael D. Reisman has been an Assistant Attorney General in the Health Care Bureau of the Office of the New York State Attorney General since 2012, where he investigates and brings enforcement actions against insurers, providers, drug companies and other individuals and entities that engage in fraudulent, misleading, deceptive, or illegal practices in the health care market. Prior to joining the Attorney General's Office, he was a commercial litigator with several prominent national law firms, handling health care, commercial, intellectual property, antitrust, and civil rights litigation in courts around the country. In private practice, he had a central role in several cases that advanced the rights of consumers in the mental health system. Mr. Reisman also has a background in the health care field. Prior to receiving his law degree from the Benjamin N. Cardozo School of Law, he was a therapist in inpatient and outpatient mental health facilities in California, New York City, and the Czech Republic, where he was a Fulbright Scholar and lived for four years. He has also taught psychology and organizational development courses. He has an M.A. in Psychology from the California Institute of Integral Studies and a B.A. from Williams College.

  • Pain Self-Management in the Context of Addiction (1.5 CME)

    Product not yet rated Contains 3 Component(s), Medical Credits Offered

    This workshop will review recommendations and current evidence related to self-management or self-directed pain management. Topics discussed will include: psychological self-help, behavioral approaches, online support, group support, nutrition, graded exercise, and the use of OTC devices (e.g. TENS), self-guided movement therapies, and alternative/complementary approaches.

    The successful management of chronic pain most often requires comprehensive approaches that include self-care, psychological, functional-restorative, and alternative-integrative approaches to complement medical treatments. Unfortunately, many patients with chronic pain lack access to integrated multidisciplinary care; under these circumstances patient education and pain self-management may play a critical role in recovery, especially in the context of substance use disorders. Self-management or self-directed approaches may include psychological self-help, behavioral approaches, online support, group support, nutrition, graded exercise, the use of OTC devices (e.g. TENS), self-guided movement therapies, spirituality and other approaches. In addition, it is crucial to motivate patients and their families to become active participants in their own treatment process. This workshop serves to review: a) the current evidence regarding the effectiveness of self-help modalities, b) methods to engage patients in the recovery process, c) the addiction specialist's role in prescribing and monitoring pain self-management activities, and d) a case study with audience participation.

    Mel Pohl

    MD, DFASAM

    Mel Pohl, MD, DFASAM is a Board Certified Family Practitioner. He is the Medical Director of Las Vegas Recovery Center (LVRC). Dr. Pohl was a major force in developing LVRCs Chronic Pain Recovery Program. He is certified by the American Board of Addiction Medicine (ABAM), and a Fellow of the American Society of Addiction Medicine (ASAM). Dr. Pohl is a Clinical Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the University of Nevada School of Medicine. He is a nationally known public speaker and co-author of Pain Recovery: How to Find Balance and Reduce Suffering from Chronic Pain (Central Recovery Press, 2009); Pain Recovery for Families: How to Find Balance When Someone Elses Chronic Pain Becomes Your Problem Too (Central Recovery Press, 2010). Dr. Pohl is the author of A Day without Pain (Central Recovery Press, 2008), which won a silver medal from Independent Publisher Book Award in May 2009. His new book writtten with Kathy Ketcham is The Pain Antidote: The Proven Program to Help You Stop Suffering From Chronic Pain, Avoid Addiction to Painkillers - and Reclaim Your Life (DeCapo). Las Vegas Recovery Center- Salary- Medical Director

    Stephen Colameco

    MD, MEd, DFASAM

    Stephen Colameco, MD, DFASAM currently serves as a medical director for Paradigm Management Services, specializing in workers' compensation chronic pain and catastrophic cases when opioids are prescribed. Dr. Colameco has served as a medical director for addiction treatment programs, as a family medicine residency director, and as an addiction specialist for psychiatric treatment programs. He is the author of two chronic pain self-help books as well as several articles published in peer-reviewed journals. He is a clinical assistant professor in the Department of Family Medicine at the Rowan University School of Osteopathic Medicine, Stratford, NJ.

Annual Conference Presenters

Name

Disclosure Information

Anthony J. Accurso, MD

Nothing to Disclose

Arpana Agrawal, PhD

Nothing to Disclose

Barbara Andraka-Christou, JD

Nothing to Disclose

Elie Aoun, MD

Nothing to Disclose

Soraya Asadi, MD, DABAM

Nothing to Disclose

Genie L. Bailey, MD

Nothing to Disclose

Joshua Barclay, MD, MS, MSHR, FACP

Nothing to Disclose

Gabriela Barnett, MA

Nothing to Disclose

Gavin Bart, MD PhD FASAM FACP

Nothing to Disclose

Kaitlan Baston, MD

Nothing to Disclose

Lou Baxter, MD, FASAM

Nothing to Disclose

Inna Belfer, MD, PhD

Nothing to Disclose

Lia Bennett, MPH

Nothing to Disclose

Michael F Bierer, MD MPH

Nothing to Disclose

Adam Bisaga, MD

Alkermes, Inc (Self) : Other Financial or Material Support (Status: Ongoing), received research suport (Status: Ongoing)

Richard D. Blondell, MD

Nothing to Disclose

Katharine Bradley, MD MPH

Nothing to Disclose

Adam C. Brooks, PhD

Nothing to Disclose

E Marshall Brooks, PhD

Nothing to Disclose

Lawrence S. Brown, MD, MPH, FASM

CDC Foundation: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Randall Brown, MD, PhD, FASAM

Nothing to Disclose

Richard Brown, MD, MPH

Wellsys, LLC: Ownership Interest includes stock, stock options, patent or other intellectual property

Greg Bunt, MD

Nothing to Disclose

Rachael Burgower, MA

Nothing to Disclose

Ryan Caldeiro, MD

Nothing to Disclose

Melinda Campopiano, MD

Nothing to Disclose

Katherine V. Carroll, PA-C

Nothing to Disclose

Mady Chalk, PhD, MSW

Nothing to Disclose

Yuchiao Chang, PhD

Nothing to Disclose

Faye Chao, MD

Nothing to Disclose

Margaret S. Chisolm, MD

Nothing to Disclose

Veronic Clair, MD, MSc, CCFP, FRCPC, PhD

Nothing to Disclose

H. Westley Clark, MD, JD, MPH, FASAM

Nothing to Disclose

Kelly Clark, MD, MBA, FASAM

Nothing to Disclose

Diana Coffa, MD

Nothing to Disclose

Stephen Colameco, MD, MEd, FASAM

Nothing to Disclose

Sophie Collins, MD

Nothing to Disclose

Wilson M. Compton, MD, MPE

3M Corp.: Ownership Interest includes stock, stock options, patent or other intellectual property

General Electric Co.: Ownership Interest includes stock, stock options, patent or other intellectual property

Pfizer, Inc.: Ownership Interest includes stock, stock options, patent or other intellectual property

Micah T. Conti, BA

Nothing to Disclose

Roxanne Cook, RN

Nothing to Disclose

Desiree A Crevecoeur-MacPhail, PhD

Nothing to Disclose

Andrew A. Danzo,

Nothing to Disclose

Smita Das, MD

Nothing to Disclose

Amy Davis, DO, MS, FACP, FAAHPM

Nothing to Disclose

Corey Davis, JD, MSPH

Nothing to Disclose

Michael A. Dekker, DO

Nothing to Disclose

Caroline M. DuPont, MD

Nothing to Disclose

Paul H. Earley, MD, DFASAM

Alkermes, Inc.: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Earley COnsulatncy, LLC: Employment

Georgia Professionals Health Program: Employment

RiverMend Health : Consultant/Advisory Board

Ryan Eisenacher,

Nothing to Disclose

Sheri Eisert, PhD

Nothing to Disclose

Honora Englander, MD

Nothing to Disclose

David H. Epstein, PhD

Nothing to Disclose

Igor Epstein, DO

Nothing to Disclose

Anthony Estreet, PhD

Nothing to Disclose

Oluwaseun Falade, MD

Nothing to Disclose

Patrick Fehling, MD

Nothing to Disclose

David Festinger, PhD

Nothing to Disclose

David A. Fiellin, MD

Pinney Associates: Consultant/Advisory Board

Michael Fingerhood, MD

Nothing to Disclose

Marc Fishman, MD, FASAM

Maryland Treatment Centers: Employment, Ownership Interest includes stock, stock options, patent or other intellectual property

US World Meds: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Jessica N. Flori, BA

Nothing to Disclose

Thomas E. Freese, PhD

Nothing to Disclose

John Fromson, MD

Nothing to Disclose

Jessie Gaeta, MD

Nothing to Disclose

Marc Galanter, MD

Nothing to Disclose

Eliot L. Gardner, PhD

Nothing to Disclose

David R. Gastfriend, MD

Nothing to Disclose

Shareh Ghani, MD

Nothing to Disclose

Udi Ghitza, PhD

Nothing to Disclose

David Goldman, MD

Nothing to Disclose

R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

Center for Health & Innovation Learning (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Hazelden Betty Ford Foundation (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

David A. Gorelick, MD, PhD, DLFAPA

Nothing to Disclose

Kevin Gray, MD

Nothing to Disclose

William Greaves, MD, MSPH

Nothing to Disclose

Traci Green, PhD, MSc

Nothing to Disclose

Mark K. Greenwald, PhD

Indivior: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Jessica Gregg, MD, PhD

Nothing to Disclose

Allison F. Hall, BS

Nothing to Disclose

Susan Hayashi, PhD

Nothing to Disclose

Gary Henschen, MD LFAPA

Nothing to Disclose

Sara K. Hertzel, BA

Nothing to Disclose

Marilyn A. Huestis, PhD

Nothing to Disclose

Andrew Huff, LPC

Nothing to Disclose

Brian Hurley, MD, MBA

Nothing to Disclose

Polly Ingram, BA

Nothing to Disclose

Krystyna R. Isaacs, PhD

Nothing to Disclose

J Harry Isaacson, MD

Nothing to Disclose

Benjamin D. Johnson, DO

Nothing to Disclose

Matthew W. Johnson, PhD

Nothing to Disclose

Hendree E. Jones, PhD

Nothing to Disclose

Jolene Joseph, LISW

Nothing to Disclose

Alene Kennedy-Hendricks, PhD

Nothing to Disclose

Jag H. Khalsa, MS, PhD

Nothing to Disclose

Sonnie Kim, PharmD

Braeburn Pharmaceuticals: Employment

Kaylin Klie, MD

Nothing to Disclose

Andrea Kline-Simon, MS

Nothing to Disclose

George Kolodner, MD

Nothing to Disclose

Philip Todd. Korthuis, MD, MPH

Nothing to Disclose

Henry R. Kranzler, MD

Alkermes: Consultant/Advisory Board

Lundbeck Pharmaceuticals: Consultant/Advisory Board, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Member of Amer Soc Clin Psychopharmacology's Alcohol Clinical Trials Initiative, supported by Alkermes, Lilly, Lundbeck, AbbVie, and Ethypharm : Consultant/Advisory Board

Otsuka Pharmaceuticals: Consultant/Advisory Board

Mark l. Kraus, MDDFASAM

Nothing to Disclose

Kevin Kunz, MD

Nothing to Disclose

JoAn Laes, MD

Nothing to Disclose

Shenghan Lai, MD, MPH

Nothing to Disclose

Bernard Le Foll, MD, PhD, MCFP

Bioprojet: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

GW pharma: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support

Mettrum: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Pfizer: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Joshua D. Lee, MD, MSc

Alkermes, Inc: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Anne Leopold, MSc

Nothing to Disclose

Petros Levounis, MD, MA

Nothing to Disclose

Chris Lewis, MA

Nothing to Disclose

Thomas Lincoln, MD

Nothing to Disclose

Raye Z. Litten, PhD

Nothing to Disclose

Michelle Lofwall, MD

Braeburn: Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

CVS Caremark: Consultant/Advisory Board

Orexo: Consultant/Advisory Board

PCM Scientific: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

David Lott, MD, FAPA, FASAM

Nothing to Disclose

Peter Luongo, PhD

Nothing to Disclose

Lauren MacAfee, MD

Nothing to Disclose

Jose R. Maldonado, MD, FAPM, FACFE

Nothing to Disclose

Herbert L Malinoff, MD, FACP, DFASAM

Nothing to Disclose

Ajay Manhapra, MD

Nothing to Disclose

Alex Manini, MD, MS

Nothing to Disclose

David Marcovitz, MD

Nothing to Disclose

Laura Martin, MD

Nothing to Disclose

Steven C. Matson, MD

Nothing to Disclose

Alexis K Matusiewicz, PhD

Nothing to Disclose

David Mee-Lee, MD

Nothing to Disclose

Kathleen Meyers, PhD

Nothing to Disclose

Jennifer Michaels, MD

Nothing to Disclose

David Miller, MD

Nothing to Disclose

William R Miller, PhD

Guilford Press (Self) : Royalties (Status: Ongoing)

Ivan Montoya, MD, MPH

Nothing to Disclose

Landhing M. Moran, PhD

Nothing to Disclose

Dan Morhaim, MD

Nothing to Disclose

Warren Morris, MD FASAM

Nothing to Disclose

Howard B. Moss, MD

Nothing to Disclose

Sam Muszynski, JD

Nothing to Disclose

Lewis Nelson, MD

Nothing to Disclose

Doug Nemecek, MD, MBA

Nothing to Disclose

Edward Nunes, MD

Nothing to Disclose

Patrick O'Connor, MD, MPH, FACP

Nothing to Disclose

Yngvild Olsen, MD, MPH

Nothing to Disclose

Nicholas A. Pace, MD

Nothing to Disclose

Patricia Pade, MD

Nothing to Disclose

Stephen Patrick, MD, MPH, MS

Vermont Oxford Network (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- 12/2015)

Joseph Perpich, MD, JD

Nothing to Disclose

Heather Peterson, PA-C

Nothing to Disclose

Karran Phillips, MD, MSc

Nothing to Disclose

Mel Pohl, MD, FASAM

Las Vegas Recovery Center: Employment

Cara Poland, MD, MEd

Nothing to Disclose

Sabrina Poole, PsyD

Nothing to Disclose

Lantie Quinones, MD

Nothing to Disclose

Darius Rastegar, MD

Nothing to Disclose

James Ray, PharmD

Alchemy Consulting, P.C.: Ownership Interest includes stock, stock options, patent or other intellectual property

Michael D Reisman, JD

Nothing to Disclose

Traci Rieckmann, PhD

Nothing to Disclose

Richard K. Ries, MD

Nothing to Disclose

Megan M. Risi, BS

Nothing to Disclose

Deidra Y Roach, MD

Nothing to Disclose

Maureen Roberts, MD

Nothing to Disclose

Sarah CM. Roberts, DrPH

Nothing to Disclose

Naoko A. Ronquest, PhD

Nothing to Disclose

Robert Roose, MD, MPH, FASAM

Nothing to Disclose

Richard N. Rosenthal, MD

Braeburn Pharmaceticals: Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Alphonse Ken Roy, MD, FASAM, DLFAPA

Nothing to Disclose

Payel Roy, MD

Nothing to Disclose

Gregory Rudolf, MD, FASAM

Nothing to Disclose

Beth A. Rutkowski, MPH

Nothing to Disclose

Kelley Saia, MD,

Nothing to Disclose

Richard Saitz, MD, MPH, FASAM

Nothing to Disclose

Edwin A. Salsitz, MD, DFASAM

Nothing to Disclose

Ruchi Sanghani, MA

Nothing to Disclose

Rebekah Savage, MD, MPH

Nothing to Disclose

Zev Schuman-Olivier, MD

Nothing to Disclose

Robert Schwartz, MD

Reckitt Benckiser: Consultant/Advisory Board

Daniel A. Schwarz, MD, CMRO

Nothing to Disclose

Peter Selby, MBBS, FCFP, dipABAM

Bristol Meyer Squibb: Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Johnson and Johnson: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support

Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Nadav Shalit, MD

Nothing to Disclose

Randi G. Sokol, MD, MPH, MMedEd

Nothing to Disclose

Robert Sokol, MD

Nothing to Disclose

Rachel Solotarof, MD, MCR

Nothing to Disclose

Christopher Stauffer, MD

Nothing to Disclose

Robert Sterling, PhD

Nothing to Disclose

Kenneth Stoller, MD

Nothing to Disclose

Geetha Subramaniam, MD, DFAPA

Nothing to Disclose

Angela Suen, BS

Nothing to Disclose

Brian Suffoletto, MD, MS

healthStratica (Self) : Royalties (Status: Ongoing)

Fatimah Tahil, MD, MPH, DFAPA, FAPM

Nothing to Disclose

John Teal, MD

Nothing to Disclose

Mishka Terplan, MD, MPH, FACOG, FASAM

Nothing to Disclose

Sebastian T. Tong, MD, MPH

Nothing to Disclose

Paul A. Trowbridge, MD, MPH

Nothing to Disclose

Allison Verbyla, MPH Candidate

Nothing to Disclose

Annmarie Lyn. Vilkins, DO, MSc

Nothing to Disclose

Hoa Vo, PhD

Nothing to Disclose

Frank Vocci, PhD

Braeburn Pharmaceuticals: Consultant/Advisory Board, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Demerx: Consultant/Advisory Board

Pinney Associates: Consultant/Advisory

Reckitt-Benckiser Pharmaceuticals: Consultant/Advisory Board, Speaker/Honoraria includes speakers bureau, symposia, and expert witness

Nora D Volkow, MD

Nothing to Disclose

Sarah E. Wakeman, MD

Nothing to Disclose

Alexander Y. Walley, MD, MSc

Nothing to Disclose

James Walsh, MD

Nothing to Disclose

Vickie Walters, LCSW-C

Nothing to Disclose

Mark Ware, BA, MBBS, MRCP(UK), MSc

Canadian Consortium for the Investigation of Cannabinoids : Employment

CanniMed: Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received

Damien Christopher Warsavage, YE-CRS, CRS

Nothing to Disclose

Michael F. Weaver, MD, FASAM

Nothing to Disclose

Melissa Weimer, DO, MCR

Nothing to Disclose

Mark A Weiner, MD, DFASAM

Nothing to Disclose

Constance Weisner, DrPH, LCSW

Nothing to Disclose

Leana Wen, MD, MSc

Nothing to Disclose

Joseph Westermeyer, MD, PhD, MPH

Nothing to Disclose

Timothy Wiegand, MD, DABAM, FACMT, FAACT

Nothing to Disclose

Bonnie b. Wilford, MS

Nothing to Disclose

Jeffrey Wilkins, MD, FASAM, DFAPA

Nothing to Disclose

Justin Wolfe, MSW, LCSW, CADC

Nothing to Disclose

Li-Tzy Wu, ScD RN MA

Nothing to Disclose

Martha J. Wunsch, MD FAAP FASAM

Nothing to Disclose

Stephen Wyatt, DO

Nothing to Disclose

Annual Conference Planning Committee

Name

Disclosure Information

Anthony Paul Albanese, MD, DFASAM

Gilead Sciences: speaker/ad board, honorarium; AbbVie Pharmaceuticals: speaker/ad board, honorarium; Merck Pharmaceuticals: speaker/ad board, honorarium; Genentech Pharmaceuticals: speaker/ad board, honorarium

Gavin Bart, MD, PhD, FASAM, FACP

Nothing to Disclose

Susan Kaye Blank, MD, DFASAM

Nothing to Disclose

Michael A. Dekker, DO

Nothing to Disclose

Christina M. Delos Reyes, MD, FASAM

Nothing to Disclose

Michael Fingerhood, MD, FACP

Nothing to Disclose

Peter David Friedmann, MD, MPH, FACP, DFASAM

Alkermes: In-Kind Support, Research; Orexo: Honoraria, Facilitated roundtable; Indivior: Honoraria, Advisory Board

Adam J. Gordon, MD, MPH, FACP, CMRO, DFASAM

Nothing to Disclose

Joshua D. Lee, MD MSc

Does Disclose

Michelle Lofwall, MD, DFASAM

Does Disclose

Joseph Montgomery Matta, MD, FASAM

Nothing to Disclose

Mark P. Schwartz, MD, FASAM

Nothing to Disclose

Sarah E. Wakeman, MD

Nothing to Disclose

Mark A. Weiner, MD, DFASAM

Nothing to Disclose

Norman Wetterau, MD, FAAFP, DFASAM

Nothing to Disclose

CME Committee

Name

Disclosure Information

Adam J. Gordon, MD, MPH, FACP, FASAM, CMRO, Chair, Reviewer

Nothing to Disclose

Catherine Friedman, MD

Vice Chair

Nothing to Disclose

Noel Ilogu, MD, MRCP

Nothing to Disclose

Hebert L. Malinoff, MD, FACP, FASAM

Nothing to Disclose

Edwin A. Salsitz, MD, FASAM, Reviewer

Nothing to Disclose

John C. Tanner, DO, FASAM, CCFC, MRO

Reckitt-Benckiser: Honorarium, Speaker; Orexo: Honorarium, Speaker; BDSI: Honorarium, Speaker & Consultant

Learning Objectives

At the conclusion of the conference, participants should be able to:

  • Employ current and new clinical approaches to treatment in a variety of settings.
  • Utilize and promote evidence-based approaches for clinical treatment of substance abuse disorders.
  • Recognize issues that arise when treating individuals in diverse and special populations or with special physical, health and mental illnesses.
  • Identify, diagnose, and treat substance use disorders in clinical populations.
  • Describe the development of new science and treatments in addiction medicine.

Accreditation Council for Continuing Medical Education

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ASAM has designated this enduring material for a maximum of 69 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABAM Maintenance of Certification Program (MOC)

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 69 AMA PRA Category 1 Credits for completing the ASAM 47th Annual Conference and Pre-Courses.

Who should attend:
  • Physicians and Clinicians
  • Researchers and Academics
  • Counselors and Students
  • Other Health Care Professionals

Dedicated to increasing access and improving the quality of addiction treatment and care.